Argentina is the third-largest pharmaceutical market in Latin Aཧmerica, with retail drug sales of USD 4.7bn in 2019. The country has ♋a large and ageing population, a relatively developed public health system, and a small but consolidated private health insu⛄rance system. The economic💟 recession in the country in 2019, aggravated by the public debt crisis and falling foreign exchange reserves, led to a contraction o📖f the domestic retail drug market. ♎;Drug sales dropped b𒆙oth in volume and US dollar terms, while drug imports decreased at a double-digit rate. On t💝h🦄e other hand, despite the fragile public finances in 2020, the government ramped up public h♚ealth spending to contain the COVID-19 pandemic. Funds were alloca🍸ted not only to drugs and medical equipment for the treatment of COVID-19 patients, but also to enhance digitalisation of the national health system.​

This report provides a complete and detailed analysꦗis of the tourism sector for Brazil. EMIS Insights presents in-depth business intelligence in a standard format across countries and regionไs, providing a balanced mix between analysis and data.

What this report allows you to do:

• Understand the key elements at play in the healthcare and pharmaceutical sector in Argentina
• Access forecasts for growth in the sector
• View key data on healthcare spending and health insurance in Argentina
• Crystallise the forces both driving and restraining this sector in Argentina
• Build a complete perspective on sector trade, investment and employment
• Understand the competitive landscape and who the major players are
• View M&A activity and major deals
• Gain an understanding of the regulatory environment for the sector in Argentina
• Build a clear picture of trends and issues for subsectors (medical institutions, pharmaceuticals manufacturing and distribution channels)

See below for a complete table of report contents🎀: